Both HIV-1 and METH can cause behavioral changes and brain injury, but their interaction is poorly understood. In the current funding period, we observed that a one-time METH binge caused a reduction in hippocampal post-tetanic potentiation only in HlV/gp120-transgenic (tg) but not control mice. RNA expression studies indicated that both HIVgp120 and METH trigger significant changes of glutamatergic and GABAergic neurotransmission. In vitro studies showed that METH at 100 pM increased neurotoxicity of HIVgp120 and excitotoxic NMDA. METH also increased HIV infection of human macrophages in association with down-regulation of at least four interferon-inducible genes. Therefore, the overall hypothesis is that use of METH aggravates behavioral disturbances and neurotoxicity associated with HIV-1 infection.
Our Specific Aims are to: (1) identify affected neural networks by studying gene expression associated with long-term effects of METH in HlVgp120- and iTat-tg and non-tg control mice and to relate such gene expression changes to behavioral performance; (2) determine whether METH interferes with the efficacy of cART drugs to reduce viral replication and production of neurotoxic products by infected monocytes/macrophages.
For Aim 1, gp120- and iTat-tg and non-tg control mice will be treated with a novel chronic, low dose 12-week METH regimen. Following a 5-month abstinence period and behavioral testing, neuronal and glial injury and gene expression will be analyzed in brain tissue using deconvolution microscopy, microarray and qRT-PCR. Gene expression data will be analyzed separately for cortex, hippocampus, striatum and other brain regions, and correlated with behavioral outcomes and neuropathology. Follow-up studies to gene expression analyses will probe protein expression, localization and function using biochemical and microscopy approaches.
For Specific Aim. 2, macrophages infected with HIV will be treated with ARV combinations and varying METH concentrations. The neurotoxicity of supernatents from such macrophage experiments will be tested on rat microglia depleted mixed neuronal glial cerebrocortical cells. The long-term objective is to identify neurotoxic mechanisms that are potential targets for therapeutic intervention.

Public Health Relevance

Infection with HIV-1 is often associated with exposure to addictive drugs, such as Methamphetamine (METH), and both are major public health concerns. Our studies will improve the understanding of mechanism contributing to brain injury and behavioral alterations caused by the combination of METH exposure and HIV infection and thus will help to develop new treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA026306-10
Application #
9493427
Study Section
Special Emphasis Panel (ZDA1)
Project Start
2009-09-30
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Soontornniyomkij, Virawudh; Umlauf, Anya; Soontornniyomkij, Benchawanna et al. (2018) Association of antiretroviral therapy with brain aging changes among HIV-infected adults. AIDS 32:2005-2015
Thaney, Victoria E; Sanchez, Ana B; Fields, Jerel A et al. (2018) Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research. J Neurovirol 24:156-167
Kesby, James P; Chang, Ariel; Markou, Athina et al. (2018) Modeling human methamphetamine use patterns in mice: chronic and binge methamphetamine exposure, reward function and neurochemistry. Addict Biol 23:206-218
Hoenigl, Martin; Jain, Sonia; Moore, David et al. (2018) Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. Emerg Infect Dis 24:
Moore, David J; Pasipanodya, Elizabeth C; Umlauf, Anya et al. (2018) Individualized texting for adherence building (iTAB) for methamphetamine users living with HIV: A pilot randomized clinical trial. Drug Alcohol Depend 189:154-160
MacDuffie, Katherine E; Brown, Gregory G; McKenna, Benjamin S et al. (2018) Effects of HIV Infection, methamphetamine dependence and age on cortical thickness, area and volume. Neuroimage Clin 20:1044-1052
Stecher, M; Chaillon, A; Eis-Hübinger, A M et al. (2018) Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. Clin Microbiol Infect :
Stecher, Melanie; Chaillon, Antoine; Eberle, Josef et al. (2018) Molecular Epidemiology of the HIV Epidemic in Three German Metropolitan Regions - Cologne/Bonn, Munich and Hannover, 1999-2016. Sci Rep 8:6799
Oppenheim, Hannah; Paolillo, Emily W; Moore, Raeanne C et al. (2018) Neurocognitive functioning predicts frailty index in HIV. Neurology 91:e162-e170
Walker, Keenan A; Brown, Gregory G (2018) HIV-associated executive dysfunction in the era of modern antiretroviral therapy: A systematic review and meta-analysis. J Clin Exp Neuropsychol 40:357-376

Showing the most recent 10 out of 148 publications